FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol
The U.S. Food and Drug Administration (FDA) announced plans to establish a new regulatory pathway for hemp-derived cannabidiol (CBD), stating that existing foods and dietary supplement authorities provide only limited tools for managing many of the risks associated with CBD products. The agency claims a new regulatory pathway would benefit consumers by providing safeguards and oversight to manage and minimize risks related to CBD products. The FDA also denied three citizen petitions from the Consumer Health Products Association (CHPA), the Council For Responsible Nutrition (CRN), and the Natural Products Association (NPA) requesting rule-making to allow the marketing of CBD products as dietary supplements.
See the remainder of US Hemp Roundtable’s Statement here.
We hope that the FDA will continue to work with the hemp industry in hopes that we find a path forward to protect CBD and our growing market. As Texans, we believe that regulating CBD will help our market continue to flourish and open to market areas for this commodity. We have advocated in Washington DC on this very issue with little to no objection from legislators, however FDA seems it is necessary to create a more lengthy process to regulate which could cost our industry more issues.
About the Texas Hemp Coalition:
The Texas Hemp Coalition’s goal is to provide industry specific information to growers, processors and entities that will be involved in the Texas Hemp Industry. We will serve as an advocacy, educational and networking liaison to reputable entities within the hemp industry.
